Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Transmedics Group Inc (TMDX)

Transmedics Group Inc (TMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,483,970
  • Shares Outstanding, K 34,174
  • Annual Sales, $ 441,540 K
  • Annual Income, $ 35,460 K
  • EBIT $ 96 M
  • EBITDA $ 116 M
  • 60-Month Beta 2.06
  • Price/Sales 10.43
  • Price/Cash Flow 83.02
  • Price/Book 13.14

Options Overview Details

View History
  • Implied Volatility 56.51% (+3.87%)
  • Historical Volatility 64.59%
  • IV Percentile 28%
  • IV Rank 15.39%
  • IV High 124.49% on 02/27/25
  • IV Low 44.14% on 06/10/25
  • Expected Move (DTE 8) 8.81 (6.72%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 1,112
  • Volume Avg (30-Day) 1,225
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 28,460
  • Open Int (30-Day) 31,015
  • Expected Range 122.40 to 140.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.41
  • Number of Estimates 7
  • High Estimate 0.55
  • Low Estimate 0.28
  • Prior Year 0.19
  • Growth Rate Est. (year over year) +115.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.04 +18.17%
on 11/14/25
156.00 -15.89%
on 12/02/25
+8.82 (+7.21%)
since 11/10/25
3-Month
107.22 +22.37%
on 10/10/25
156.00 -15.89%
on 12/02/25
+23.42 (+21.73%)
since 09/10/25
52-Week
55.00 +138.56%
on 01/21/25
156.00 -15.89%
on 12/02/25
+62.22 (+90.19%)
since 12/10/24

Most Recent Stories

More News
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference

ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 131.21 (-2.66%)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 131.21 (-2.66%)
TransMedics: Q3 Earnings Snapshot

TransMedics: Q3 Earnings Snapshot

TMDX : 131.21 (-2.66%)
TransMedics Reports Third Quarter 2025 Financial Results

ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 131.21 (-2.66%)
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025

ANDOVER, Mass. , Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 131.21 (-2.66%)
TransMedics Group (TMDX) Gets a Buy from Canaccord Genuity

In a report released yesterday, William Plovanic from Canaccord Genuity reiterated a Buy rating on TransMedics Group, with a price target of $142.00. The company’s shares closed yesterday at $111.71.Elevate...

TMDX : 131.21 (-2.66%)
TransMedics Group Acquires Aircraft for Organ Transport

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransMedics...

TMDX : 131.21 (-2.66%)
Oppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)

In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group, with a price target of $150.00. The company’s shares closed yesterday at $116.07.Elevate Your Investing...

TMDX : 131.21 (-2.66%)
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy

Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion...

TMDX : 131.21 (-2.66%)
TransMedics to Present at Upcoming September Investor Conferences

ANDOVER, Mass. , Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...

TMDX : 131.21 (-2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation....

See More

Key Turning Points

3rd Resistance Point 144.45
2nd Resistance Point 140.94
1st Resistance Point 136.07
Last Price 131.21
1st Support Level 127.69
2nd Support Level 124.18
3rd Support Level 119.31

See More

52-Week High 156.00
Last Price 131.21
Fibonacci 61.8% 117.42
Fibonacci 50% 105.50
Fibonacci 38.2% 93.58
52-Week Low 55.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar